Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dicerna Pharmaceuticals Inc.

www.dicerna.com

Latest From Dicerna Pharmaceuticals Inc.

BI’s Business Development Focus Remains On Early Collaboration

Boehringer Ingelheim’s US business development head Ioannis Sapountzis outlines BI’s efforts to catch up with competitors in NASH and immuno-oncology via early-stage partnerships and licensing deals.

Business Strategies Research and Development Strategies

Boehringer Bigs Up US and China As Europe Sales Slip

Away from the pricing pressures, reimbursement battles and problems of patent expiries in its home continent, the German major is counting on the US and China to provide the best opportunities for future growth.

Emerging Markets Sales & Earnings

Win-Win For Alnylam And Dicerna With RNAi Trade Secrets Settlement

Although Dicerna needs to make some payments to Alnylam to settle a patent infringement case, the company has avoided an expensive court trial and is free to find partners for its early-stage RNAi therapeutics programs.

Intellectual Property Rare Diseases

Boehringer Ingelheim Confident Of A Happier Ending In NASH Than HCV

With a Phase II AOC3 inhibitor and a pair of preclinical partnerships with RNAi companies, the German pharma is taking its time to investigate a variety of approaches to the multi-factorial disease.

Research & Development Liver & Hepatic
See All

Company Information

  • Industry
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
    • Nanotechnology, Chips, etc.
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
      • Site Specific
  • Therapeutic Areas
  • Cardiovascular
  • Hepatic (Liver)
  • Infectious & Viral Diseases
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Dicerna Pharmaceuticals Inc.
  • Senior Management
  • Douglas C Fambrough, III, PhD, Pres. & CEO
    Jack Green, CFO
    Bob D Brown, PhD, SVP, CSO
    James B Weissman, CBO
  • Contact Info
  • Dicerna Pharmaceuticals Inc.
    Phone: (617) 621-8097
    87 Cambridge Park Dr.
    Cambridge, MA 02140
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register